Iowa State University Research Foundation Inc

Virginia Tech Intellectual Properties Inc

Terns Pharmaceuticals, Inc.

Novartis Ag

Martijn Fenaux

Xiang-Jin Meng

Patrick G Halbur

F Anthony Romero

Christopher T Jones

Corey Reeves

Oliver L Saunders

Fumiaki Yokokawa

Weidong Zhong

Zachary Kevin Sweeney

Xiaodong Lin

Sampath-Kumar Anandan

Liang Mao

Virender Singh Aulakh

Gary W Luehr

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.

Compounds as GLP-1R agonists

The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.

Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof

The present invention provides a compound of Formula (I) or a salt thereof; 

Alkynyl nucleoside analogs as inhibitors of human rhinovirus

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.

The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R, R, R, R, Rand Z are defined herein, which is a 2'-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.

2'-ethynyl nucleoside derivatives for treatment of viral infections

The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R, R, R, R, Rand Z are as defined herein, which is a 2'-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue fever, yellow fever, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.

2'-Ethynyl nucleoside derivatives for treatment of viral infections

Growing community of inventors

San Mateo, CA, United States of America

Martijn Fenaux